Pfizer hands Bosulif Phase III to venture-backed drug developer
This article was originally published in Scrip
Executive Summary
Pfizer has signed a late-stage clinical development deal with venture-backed drug developer Avillion, to carry out a Phase III trial for cancer drug Bosulif in order to expand the drug's indication to include first-line treatment for chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). While the need to seek the services of a start-up company in developing its drug might be seen as an embarrassment for more pharma companies with more machismo, Pfizer sees the deal as a way of more rapidly exploiting the potential of Bosulif.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.